Advate (Antihemophilic Factor) - Drug Interactions, Contraindications, Overdosage, etc

DRUG INTERACTIONS

ADVATE drug label information in our database does not contain a dedicated section on drug interactions. Please check subsections of WARNINGS AND PRECAUTIONS as well as other sources.

CONTRAINDICATIONS

Known hypersensitivity to mouse or hamster proteins may be a contraindication to the use of ADVATE rAHF-PFM (see PRECAUTIONS). Known intolerance or allergic reaction to any of the constituents in the formulation may be a contraindication to the use of ADVATE rAHF-PFM. ADVATE rAHF-PFM is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product.

REFERENCES

1. Aledort L: Inhibitors in hemophilia patients: Current status and management. Am J Hematol 47:208-217, 1994.
2. Kessler CM: An introduction to factor VIII inhibitors: The detection and quantitation. Am J Med 91 (Suppl 5A):1S-5S, 1991.
3. Lusher J, Arkin S, Hurst D: Recombinant FVIII (Kogenate) treatment of previously untreated patients (PUPs) with hemophilia A. Update of safety, efficacy and inhibitor development after seven study years. Abstract no. PD-664, ISTH, Florence. Thromb Haemost (suppl.):162, 1997.
4. Gruppo R, Chen H, Schroth P, Bray GL: Safety and immunogenicity of recombinant factor VIII (Recombinate) in previously untreated patients (PUPs): A 7.3 year update. Abstract no. 291, XXIII Congress of the World Federation of Haemophilia, The Hague. Haemophilia 4:228, 1998.
5. Rothschild C, Laurian Y, Satre EP, et al: French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: Incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost 80:779-783, 1998.
6. Gringeri A, Kreuz W, Escuriola-Ettinghausen C, et al: Anti-FVIII inhibitor incidence in previously untreated patients (PUPs) with hemophilia exposed to Kogenate (G.I.P.S.I.--German-Italian PUP Study on Inhibitor). Abstract no. 2642, ISTH, Florence. Thromb Haemost (suppl.):648, 1997.
7. Courter SG, Bedrosian CL: Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hematol 38:52-59, 2001.
8. Scharrer I, Bray GL, Neutzling O: Incidence of inhibitors in haemophilia A patients--A review of studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 5:45-54, 1999.
9. Baxter Healthcare Corporation, Glendale, CA. U.S.A. Data on file, 2002.
10. White II GC, Courter S, Bray GL, et al: A multicenter study of recombinant factor VIII (Recombinate™) in previously treated patients with hemophilia A. Thromb Haemost 77:660-667, 1997.
11. Abshire TC, Brackmann H-H, Scharrer I, et al: Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy. Thromb Haemost 83:811-816, 2000.
12. Lee CA, Owens D, Bray G, et al: Pharmacokinetics of recombinant factor VIII (Recombinate) using one-stage clotting and chromogenic factor VIII assay. Thromb Haemost 82:1644-1647, 1999.
13. Fijnvandraat K, Berntorp E, ten Cate JW, et al: Recombinant, B-domain deleted factor VIII (r-VIII SQ): Pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb Haemost 77:298-302, 1997.

© Copyright 2003 Baxter Healthcare Corporation. All rights reserved.

To enroll in the confidential, industry-wide Patient Notification System, call 1-888-UPDATE U (1-888-873-2838).

Baxter, ADVATE, and RECOMBINATE are trademarks of Baxter International, Inc.

Baxter is registered in the U.S. Patent and Trademark office.

Baxter Healthcare Corporation

Westlake Village, CA 91362 USA

U.S. License No. 140

NDC 0944-2940-01/02/03/04

Issued July 2003                    LE-07-00036